Biopharmaceutical investments in targeted protein degradation (TPD), particularly Proteolysis Targeting Chimeric (PROTAC) molecules, have doubled over the past 24 months. Phase II trial data demonstrates success in clearing pathogenic proteins previously classified as undruggable.
Delivery Systems and Bioavailability
The main technical bottleneck in TPD therapeutic development remains oral bioavailability and tissue-specific delivery. Researchers are leveraging lipid nanoparticle (LNP) formulations and novel ligand designs to enhance cellular uptake while reducing off-target toxicity in liver and renal tissues.